Rocket Pharmaceuticals - RCKT Stock Forecast, Price & News

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rocket Pharmaceuticals in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" RCKT shares.
View RCKT analyst ratings or view top-rated stocks.

12 equities research analysts have issued 1 year price targets for Rocket Pharmaceuticals' stock. Their RCKT share price forecasts range from $34.00 to $75.00. On average, they expect the company's stock price to reach $52.58 in the next twelve months. This suggests a possible upside of 215.4% from the stock's current price.
View analysts price targets for RCKT or view top-rated stocks among Wall Street analysts.

Rocket Pharmaceuticals' stock was trading at $19.57 at the beginning of 2023. Since then, RCKT shares have decreased by 14.8% and is now trading at $16.67.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our RCKT earnings forecast.

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) issued its earnings results on Monday, February, 27th. The biotechnology company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by $0.10. During the same quarter in the previous year, the firm earned ($0.69) earnings per share.

ETFs with the largest weight of Rocket Pharmaceuticals (NASDAQ:RCKT) stock in their portfolio include Global X Genomics & Biotechnology ETF (GNOM), Global X Guru Index ETF (GURU), Harbor Health Care ETF (MEDI), ALPS Medical Breakthroughs ETF (SBIO), Harbor Disruptive Innovation ETF (INNO), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

Based on aggregate information from My MarketBeat watchlists, some companies that other Rocket Pharmaceuticals investors own include Nymox Pharmaceutical (NYMX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Amarin (AMRN), Energy Transfer (ET), Micron Technology (MU), VBI Vaccines (VBIV), Vaxart (VXRT) and Alibaba Group (BABA).

Rocket Pharmaceuticals trades on the NASDAQ under the ticker symbol "RCKT."

Rocket Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Maverick Capital Ltd. (4.49%), RA Capital Management L.P. (3.18%), Price T Rowe Associates Inc. MD (2.49%), Avidity Partners Management LP (2.02%), Dimensional Fund Advisors LP (1.49%) and Geode Capital Management LLC (1.46%). Insiders that own company stock include Gaurav Shah, Gotham Makker, Jonathan David Schwartz, Kinnari Patel and Rtw Investments, Lp.
View institutional ownership trends.

Shares of RCKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RCKT stock can currently be purchased for approximately $16.67.

Rocket Pharmaceuticals (NASDAQ:RCKT) has a market capitalization of $1.32 billion. The biotechnology company earns $-221,860,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis.

The company employs 151 workers across the globe.

Rocket Pharmaceuticals' mailing address is 350 FIFTH AVENUE SUITE 7530, NEW YORK NY, 10118. The official website for the company is www.rocketpharma.com. The biotechnology company can be reached via phone at (609) 659-8001, via email at investors@rocketpharma.com, or via fax at 646-224-9585.